test

Madhav V. Dhodapkar MBBS

Arthur H. Bunker and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology; Chief, Section of Hematology, Department of Internal Medicine; Clinical Research Program Leader, Hematology Program, Yale Cancer Center

Clinical Interests

Multiple myeloma; monoclonal gammopathy of unknown significance (MGUS); immunobiology of cancers


Board Certifications

1994
Hematology (Internal Medicine), Board Certified
1995
Medical Oncology, Board Certified

Patient Care Locations

madhav_dhodapkarfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Myeloid and Monocytic LeukemiaE2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, otherA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (=65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Leukemia, other(E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Multiple MyelomaA Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

More Clinical Trials...

Edit Profile